ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

Exosomes are cell-derived particles in the form of vesicles that are shown to be exuded from particular cells, like that of dendritic cells and mesenchymal stem cells, when they fuse with multi-vesicular bodies through the plasma membrane. They have an efficient therapeutic capability. The global exosome diagnostic and therapeutic market by the Asia Pacific region is estimated to grow from $XX million in 2018 to $XX million by 2027, at a CAGR of 28.19% between 2019 to 2027.

.

ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

Asia Pacific Exosome Diagnostic and Therapeutic Market by Application (Diagnostic, Therapeutic) by Product (Instrument, Reagent, Software) by End-user (Cancer Institute, Hospital, Diagnostic Center, Other End-user) by Geography.

Request free sample

Exosomes are cell-derived particles in the form of vesicles that are shown to be exuded from particular cells, like that of dendritic cells and mesenchymal stem cells, when they fuse with multi-vesicular bodies through the plasma membrane. They have an efficient therapeutic capability. The global exosome diagnostic and therapeutic market by the Asia Pacific region is estimated to grow from $XX million in 2018 to $XX million by 2027, at a CAGR of 28.19% between 2019 to 2027.

Japan, China, India, Australia, South Korea, and other countries together forming the Rest of Asia Pacific regional segment are the major economies shaping up the market trends of the regional market. The APAC region has multiple money-spinning opportunities in the exosome diagnostic and therapeutic market and the region is probably to become the fastest growing market by the end of 2027. Asia-Pacific is a solidly packed region, with China being the most populated country. So, the country’s growth, which is supplemented by the substantially larger base of cancer patients, will increase the demand for exosome diagnostic and therapeutic products. Rising demand for advanced healthcare services in the emerging economies of India and China are essentially driving the progression of the Asia-Pacific market.

The established and newly emerging cancer institute in the region are expected to proliferate throughout the analysis period in the regional market, predominantly due to the rising emphasis on the exosomes utility for cancer treatment. The rising government financial support for the exploration of groundbreaking techniques and treatment through exosome-based diagnostic & therapeutics are expected to put the cancer institutes on the top market pedestal.

Nanosomix Inc., BioCat GmbH, Exosome Diagnostics Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Codiak BioSciences, Malvern Instruments Ltd., Capricor Therapeutics, Inc., EVOX Therapeutics Ltd., Sistemic Ltd., Hitachi Chemical Diagnostics, Inc., System Biosciences (SBI), HansaBioMed Life Sciences Ltd. (acquired by Lonza), Aethlon Medical, Inc., and MBL International Corporation are some of the contending market players operating that are mentioned in the report.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • DIAGNOSTIC IS THE MAJORLY USED APPLICATION
      • SOFTWARE SEGMENT IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
      • CANCER INSTITUTES HOLD THE LARGEST MARKET SHARE IN TERMS OF END-USER
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • INCREASE IN PERVASIVENESS OF CANCER
      • RISING GOVERNMENT AND NON-GOVERNMENT INITIATIVES
      • ADVANCEMENT IN TECHNOLOGY
    • MARKET RESTRAINTS
      • CHALLENGES FACED IN THE USAGE OF EXOSOME
      • STRINGENT REGULATION
    • MARKET OPPORTUNITIES
      • LUCRATIVE GROWTH OPPORTUNITIES IN THE EMERGING ECONOMIES
      • INCREASE IN ADOPTION OF INNOVATIVE AND ADVANCED EXOSOME DIAGNOSTIC AND THERAPEUTIC PROCEDURES
    • MARKET CHALLENGES
      • LOW AWARENESS IN THE DEVELOPING COUNTRIES
  1. MARKET BY APPLICATION
    • DIAGNOSTIC
    • THERAPEUTIC
  2. MARKET BY PRODUCT
    • INSTRUMENT
    • REAGENT
    • SOFTWARE
  3. MARKET BY END-USER
    • CANCER INSTITUTE
    • HOSPITAL
    • DIAGNOSTIC CENTER
    • OTHER END-USER
  4. KEY ANALYTICS
    • PORTER’S FIVE FORCES MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF COMPETITIVE RIVALRY
    • EXOSOME ETYMOLOGY
    • PATENT ANALYSIS
    • COMPONENTS OF EXOSOME
    • OPPORTUNITY MATRIX
  5. GEOGRAPHICAL ANALYSIS
    • ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
  1. COMPETITIVE LANDSCAPE
    • COMPANY PROFILES
      • AETHLON MEDICAL, INC.
      • BIOCAT GMBH
      • CAPRICOR THERAPEUTICS, INC.
      • CODIAK BIOSCIENCES
      • EVOX THERAPEUTICS LTD.
      • EXOSOME DIAGNOSTICS INC.
      • HANSABIOMED LIFE SCIENCES LTD. (ACQUIRED BY LONZA)
      • HITACHI CHEMICAL DIAGNOSTICS, INC.
      • MALVERN INSTRUMENTS LTD.
      • MBL INTERNATIONAL CORPORATION
      • NANOSOMIX INC.
      • SISTEMIC LTD.
      • SYSTEM BIOSCIENCES (SBI)
      • THERMO FISHER SCIENTIFIC INC.
      • QIAGEN N.V.
LIST OF TABLES
TABLE 1        NOMENCLATURE OF EXOSOME PARTICLESTABLE 2        ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)TABLE 3        ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2019-2027 ($ MILLION)

TABLE 4        ASIA PACIFIC DIAGNOSTIC MARKET 2019-2027 ($ MILLION)

TABLE 5        ASIA PACIFIC THERAPEUTIC MARKET 2019-2027 ($ MILLION)

TABLE 6        ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2019-2027 ($ MILLION)

TABLE 7        ASIA PACIFIC INSTRUMENT MARKET 2019-2027 ($ MILLION)

TABLE 8        COMMERCIAL KITS AND REAGENTS EXAMPLES FOR THE ISOLATION OF EXOSOME

TABLE 9        ASIA PACIFIC REAGENT MARKET 2019-2027 ($ MILLION)

TABLE 10      ASIA PACIFIC SOFTWARE MARKET 2019-2027 ($ MILLION)

TABLE 11      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END-USER 2019-2027 ($ MILLION)

TABLE 12      ASIA PACIFIC CANCER INSTITUTE MARKET 2019-2027 ($ MILLION)

TABLE 13      ASIA PACIFIC HOSPITAL MARKET 2019-2027 ($ MILLION)

TABLE 14      EXOSOME ASSOCIATED PROTEIN IN CLINICAL DIAGNOSTICS USAGE

TABLE 15      ASIA PACIFIC DIAGNOSTIC CENTER MARKET 2019-2027 ($ MILLION)

TABLE 16      ASIA PACIFIC OTHER END-USER MARKET 2019-2027 ($ MILLION)

TABLE 17      TYPE OF PROTEINS FOUND IN EXOSOMES

TABLE 18      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

TABLE 19      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 20      ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017

LIST OF FIGURES

FIGURE 1      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 2      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY APPLICATION 2018 & 2027 (%)

FIGURE 3      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC 2019-2027 ($ MILLION)

FIGURE 4      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY THERAPEUTIC 2019-2027 ($ MILLION)

FIGURE 5      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY PRODUCT 2018 & 2027 (%)

FIGURE 6      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY INSTRUMENT 2019-2027 ($ MILLION)

FIGURE 7      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REAGENT 2019-2027 ($ MILLION)

FIGURE 8      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY SOFTWARE 2019-2027 ($ MILLION)

FIGURE 9      ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY END-USER 2018 & 2027 (%)

FIGURE 10   ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY CANCER INSTITUTE 2019-2027 ($ MILLION)

FIGURE 11   ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY HOSPITAL 2019-2027 ($ MILLION)

FIGURE 12   ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC CENTER 2019-2027 ($ MILLION)

FIGURE 13   ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY OTHER END-USER 2019-2027 ($ MILLION)

FIGURE 14   PORTER’S FIVE FORCE MODEL

FIGURE 15   NUMBER OF PAPERS PUBLISHED ON EXOSOME 2003-2017

FIGURE 16   JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 17   CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 18   INDIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 19   AUSTRALIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 20   SOUTH KOREA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

FIGURE 21   REST OF ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    • ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
  1. MARKET BY APPLICATION
    • DIAGNOSTIC
    • THERAPEUTIC
  2. MARKET BY PRODUCT
    • INSTRUMENT
    • REAGENT
    • SOFTWARE
  3. MARKET BY END-USER
    • CANCER INSTITUTE
    • HOSPITAL
    • DIAGNOSTIC CENTER
    • OTHER END-USER

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now